JP2011506607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506607A5 JP2011506607A5 JP2010539470A JP2010539470A JP2011506607A5 JP 2011506607 A5 JP2011506607 A5 JP 2011506607A5 JP 2010539470 A JP2010539470 A JP 2010539470A JP 2010539470 A JP2010539470 A JP 2010539470A JP 2011506607 A5 JP2011506607 A5 JP 2011506607A5
- Authority
- JP
- Japan
- Prior art keywords
- formulated
- dipyridamole
- unit dosage
- pharmaceutical composition
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 66
- 229960002768 dipyridamole Drugs 0.000 claims description 65
- 239000008194 pharmaceutical composition Substances 0.000 claims description 62
- 239000002552 dosage form Substances 0.000 claims description 58
- 239000003246 corticosteroid Substances 0.000 claims description 52
- 229960005205 prednisolone Drugs 0.000 claims description 52
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 52
- 238000013270 controlled release Methods 0.000 claims description 40
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 32
- 238000004090 dissolution Methods 0.000 claims description 16
- 239000011324 bead Substances 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 8
- 239000012738 dissolution medium Substances 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 229960002537 betamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 4
- 229960004436 budesonide Drugs 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229960002714 fluticasone Drugs 0.000 claims description 4
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
- 230000000495 immunoinflammatory effect Effects 0.000 claims description 4
- 229960004584 methylprednisolone Drugs 0.000 claims description 4
- 229960004618 prednisone Drugs 0.000 claims description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 2
- 238000011903 nutritional therapy Methods 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 229920003134 Eudragit® polymer Polymers 0.000 claims 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 4
- 229960001145 deflazacort Drugs 0.000 claims 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 30
- 229920003139 Eudragit® L 100 Polymers 0.000 description 2
- 229920003141 Eudragit® S 100 Polymers 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1430707P | 2007-12-17 | 2007-12-17 | |
| PCT/US2008/013805 WO2009078998A1 (en) | 2007-12-17 | 2008-12-17 | Therapeutic regimens for the treatment of immunoinflammatory disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011506607A JP2011506607A (ja) | 2011-03-03 |
| JP2011506607A5 true JP2011506607A5 (OSRAM) | 2012-02-09 |
Family
ID=40795828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539470A Pending JP2011506607A (ja) | 2007-12-17 | 2008-12-17 | 免疫炎症性障害の処置のための治療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110189293A1 (OSRAM) |
| EP (1) | EP2231129A4 (OSRAM) |
| JP (1) | JP2011506607A (OSRAM) |
| KR (1) | KR20100121601A (OSRAM) |
| CN (1) | CN101938996A (OSRAM) |
| AU (1) | AU2008338980A1 (OSRAM) |
| CA (1) | CA2709561A1 (OSRAM) |
| IL (1) | IL206435A0 (OSRAM) |
| MX (1) | MX2010006724A (OSRAM) |
| NZ (1) | NZ586332A (OSRAM) |
| WO (1) | WO2009078998A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0808537D0 (en) * | 2008-05-12 | 2008-06-18 | Archimedes Dev Ltd | Compositions |
| GB201202433D0 (en) * | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
| WO2016119701A1 (en) | 2015-01-28 | 2016-08-04 | Realinn Life Science Limited | COMPOUNDS FOR ENHANCING PPARγ EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF |
| CN106994128A (zh) * | 2016-01-26 | 2017-08-01 | 上海普瑞得生物技术有限公司 | 17-α羟孕酮化合物在预防和治疗中性粒细胞炎症疾病中的应用 |
| US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
| EP4427752A1 (en) * | 2023-03-09 | 2024-09-11 | Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Dipyridamole as a novel therapy for muscular myogenesis disorders and inflammatory arthritis |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3031450A (en) * | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
| US4034087A (en) * | 1973-12-17 | 1977-07-05 | The Regents Of The University Of Michigan | Pharmaceutical composition and process of treatment |
| US4107306A (en) * | 1973-01-16 | 1978-08-15 | The Regents Of The University Of Michigan | Process for treating proliferative skin disease |
| DD119586A5 (OSRAM) * | 1973-12-21 | 1976-05-05 | ||
| US3934036A (en) * | 1975-01-23 | 1976-01-20 | Kyorin Seiyaku Kabushiki Kaisha | N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent |
| DE2962124D1 (en) * | 1978-05-26 | 1982-03-25 | Ici Plc | Analgesic 6-acylaminotetrahydro-1,3,5-triazine-2,4-dione derivatives, pharmaceutical compositions thereof, and process for their manufacture |
| FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
| DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| BG36086A1 (en) * | 1982-01-19 | 1984-09-14 | Glbov | Method for inducing interferon |
| US4879119A (en) * | 1984-02-21 | 1989-11-07 | Yamanouchi Pharmaceutical Co., Ltd. | Patch |
| JPS60174716A (ja) * | 1984-02-21 | 1985-09-09 | Yamanouchi Pharmaceut Co Ltd | パツチ剤 |
| US4554271A (en) * | 1984-02-24 | 1985-11-19 | The Upjohn Company | Use of high doses of derivatives of 6α-methylprednisolone for the acute treatment of stroke syndrome |
| DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| AU618517B2 (en) * | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
| US5668116A (en) * | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
| US5242921A (en) * | 1988-04-27 | 1993-09-07 | Yale University | Compositions and methods for treating cutaneous hyperproliferative disorders |
| US5270047A (en) * | 1991-11-21 | 1993-12-14 | Kauffman Raymond F | Local delivery of dipyridamole for the treatment of proliferative diseases |
| US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
| EG20321A (en) * | 1993-07-21 | 1998-10-31 | Otsuka Pharma Co Ltd | Medical material and process for producing the same |
| US5428040A (en) * | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
| DE4430128A1 (de) * | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
| FR2732223B1 (fr) * | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
| US5728712A (en) * | 1995-05-19 | 1998-03-17 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
| US6265427B1 (en) * | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
| US6235706B1 (en) * | 1996-09-18 | 2001-05-22 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| US5874437A (en) * | 1996-11-01 | 1999-02-23 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| US5792476A (en) * | 1996-12-19 | 1998-08-11 | Abigo Medical Ab | Sustained release glucocorticoid pharmaceutical composition |
| US6054487A (en) * | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| KR20010013413A (ko) * | 1997-06-05 | 2001-02-26 | 피터 지. 스트링거 | 혈전성 질환의 치료 방법 |
| US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| US6602521B1 (en) * | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
| US6677326B2 (en) * | 1999-03-15 | 2004-01-13 | Arakis, Ltd. | Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6376242B1 (en) * | 1999-09-21 | 2002-04-23 | Emory University | Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents |
| US6515010B1 (en) * | 1999-11-15 | 2003-02-04 | Smithkline Beecham Corporation | Carvedilol methanesulfonate |
| WO2001047572A2 (en) * | 1999-12-29 | 2001-07-05 | Advanced Cardiovascular Systems, Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
| EP1370211A4 (en) * | 2001-03-02 | 2005-02-09 | Bristol Myers Squibb Co | SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP |
| US6960357B2 (en) * | 2001-05-25 | 2005-11-01 | Mistral Pharma Inc. | Chemical delivery device |
| SG152907A1 (en) * | 2001-07-09 | 2009-06-29 | Combinatorx Inc | Combinations for the treatment of inflammatory disorders |
| GB0119848D0 (en) * | 2001-08-15 | 2001-10-10 | Univ Sheffield | Delayed and sustained drug release |
| EP2279742A3 (en) * | 2001-10-05 | 2011-04-20 | Zalicus Inc. | Combinations for the treatment of immunoinflammatory disorders |
| US20040180812A1 (en) * | 2002-12-13 | 2004-09-16 | Technology Center | Methods of treating and preventing proliferative disease |
| JP2006515320A (ja) * | 2002-12-31 | 2006-05-25 | ラリー エル オーグスバーガー | 活性クッション性成分を含有する医薬品剤形の製造方法 |
| US20050058688A1 (en) * | 2003-02-22 | 2005-03-17 | Lars Boerger | Device for the treatment and prevention of disease, and methods related thereto |
| JP4532868B2 (ja) * | 2003-09-22 | 2010-08-25 | キヤノン株式会社 | 放射線画像処理装置 |
| TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
| CA2640484A1 (en) * | 2006-01-26 | 2007-08-09 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith |
| NZ569984A (en) * | 2006-01-27 | 2011-06-30 | Eurand Inc | Drug delivery systems comprising weakly basic drugs and organic acids |
| CA2644889A1 (en) * | 2006-03-07 | 2007-09-13 | Combinatorx, Incorporated | Compositions and methods for the treatment of immunoinflammatory disorders |
| CA2737131A1 (en) * | 2007-09-19 | 2009-03-26 | Zalicus Inc. | Therapeutic regimens for the treatment of immunoinflammatory disorders |
-
2008
- 2008-12-17 KR KR1020107015745A patent/KR20100121601A/ko not_active Withdrawn
- 2008-12-17 CN CN2008801264669A patent/CN101938996A/zh active Pending
- 2008-12-17 JP JP2010539470A patent/JP2011506607A/ja active Pending
- 2008-12-17 WO PCT/US2008/013805 patent/WO2009078998A1/en not_active Ceased
- 2008-12-17 CA CA2709561A patent/CA2709561A1/en not_active Abandoned
- 2008-12-17 US US12/808,477 patent/US20110189293A1/en not_active Abandoned
- 2008-12-17 MX MX2010006724A patent/MX2010006724A/es not_active Application Discontinuation
- 2008-12-17 NZ NZ586332A patent/NZ586332A/en not_active IP Right Cessation
- 2008-12-17 EP EP08861473A patent/EP2231129A4/en not_active Withdrawn
- 2008-12-17 AU AU2008338980A patent/AU2008338980A1/en not_active Abandoned
-
2010
- 2010-06-17 IL IL206435A patent/IL206435A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6491174B2 (ja) | ニタゾキサニドの制御放出医薬配合物 | |
| JP7573080B2 (ja) | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 | |
| JP7285222B2 (ja) | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 | |
| CA2746884A1 (en) | A method of treating insomnia | |
| JP2011511071A5 (OSRAM) | ||
| KR20070112763A (ko) | 서방성 코팅 또는 매트릭스 및 ｎｍｄａ 수용체 길항제를포함하는 조성물, 대상에 대한 상기 ｎｍｄａ 길항제의투여 방법 | |
| KR20150073944A (ko) | 악액질 및 근육감소증 치료를 위한 ｓ핀돌롤의 사용 | |
| JP6735020B2 (ja) | アマンタジン組成物を投与する方法 | |
| JP7246384B2 (ja) | 遅延放出デフェリプロン錠剤及びその使用法 | |
| JP2011506607A5 (OSRAM) | ||
| JP2011503075A (ja) | エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド | |
| JP6293678B2 (ja) | ハイドロコーチゾンの制御放出製剤 | |
| JP7436524B2 (ja) | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 | |
| JP2011506607A (ja) | 免疫炎症性障害の処置のための治療法 | |
| JP2019533672A5 (OSRAM) | ||
| EP3937928A1 (en) | Capsid assembly modulator solid formulation | |
| TWI494108B (zh) | 糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途 | |
| JP7033454B2 (ja) | Ａｅｒｄ／喘息におけるトロンボキサン受容体拮抗薬 | |
| TW201806599A (zh) | 用於快速開始抗抑鬱作用之給藥方案 | |
| JP2020504763A5 (OSRAM) | ||
| JP6420923B1 (ja) | 医薬 | |
| Aggarwal et al. | Thalidomide-The Disastrous Drug | |
| TW201642856A (zh) | Ｍｕ類鴉片受體拮抗劑與類鴉片藥劑之組合劑型 | |
| CN101287469A (zh) | 5－(2－氯苯基)－1,2－二氢－7－氟－8－甲氧基－3－甲基－吡唑并[3,4－b][1,4]苯并二氮杂䓬的给药方案 | |
| JP2025519466A (ja) | フロログルシノール製剤および使用方法 |